1'-O-methylaverantin | 28254-23-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1'-O-methylaverantin
• 英文别名: 2-(1-methoxy-hexyl)-1,3,6,8-tetrahydroxy-anthraquinone；1,3,6,8-Tetrahydroxy-2(1'-methoxyhexyl)anthrachinon；1'-Methoxy-averantin；1,3,6,8-Tetrahydroxy-2-(1-methoxyhexyl)anthracene-9,10-dione
• CAS: 28254-23-1
• 化学式: C₂₁H₂₂O₇
• 分子量: 386.401
• InChiKey: RNOYIZPXILLZCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  甲醇 、 (1'S)-1'-O-β-D-galactofuranosylaverantin 在 盐酸 作用下， 反应 18.0h， 以10.7 mg的产率得到1'-O-methylaverantin
  参考文献：
  名称：

  Quinofuracins A–E, Produced by the Fungus Staphylotrichum boninense PF1444, Show p53-Dependent Growth Suppression

  摘要：

  Quinofuracins A-E, novel anthraquinone derivatives containing beta-D-galactofuranose that were isolated from the fungus Staphylotrichum boninense PF1444, induced p53-dependent cell death in human tumor cells. The structures of quinofuracins A-E, including absolute configurations, were elucidated by extensive spectroscopic analysis and chemical transformation studies. Quinofuracins were classified into three groups according to the aglycone moieties. 5'-Oxoaverantin was present in quinofuracins A-C, whereas averantin and versicolorin B were identified in quinofuracins D and E, respectively. These quinofuracins induced p53-dependent growth suppression in human glioblastoma LNZTA3 cells.

  DOI：

  10.1021/np500581m

文献信息

• TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION
  申请人：ETH Zurich

  公开号：EP3801507A2

  公开（公告）日：2021-04-14
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.